View On Demand

A Breakthrough Solution For Sleep Apnea

About the Event

Currently more than a billion people in the world suffer from Obstructive Sleep Apnea, a condition that makes sleep difficult and can contribute to several issues including high blood pressure, Type 2 diabetes, liver problems, and severe fatigue. In fact, a recent study showed that people with sleep apnea were nearly 2.5 times more likely to be in a car wreck than the general population.

Yet, fewer than 5% of sufferers receive treatment – and most of those use CPAP machines which are so noisy, cumbersome, and inconvenient most patients discontinue use after just a few months.

To combat these problems, Sommetrics has created aerSleep II, a maskless, medical device that uses negative pressure to open the airway allowing users to breath freely while they sleep. Sommetrics has launched a pivotal clinical study and will have results in six months. Once approved the prescription device will be in market via major drug and retail chains including CVS, Walgreens, Walmart, and others in the second half of 2023.

Join our webinar to hear from Sommetrics founder and CEO, Richard Rose, as he shares details of why aerSleep II is a significant improvement over CPAPs and how they intend to make inroads in the $6B sleep apnea market.

View On-Demand Webinar


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.